World-first clinical trial launched for fridge-free vaccine that could revolutionise healthcare
The UK is paving the way for medical advancement with the launch of a first-of-its-kind clinical trial of a vaccine that doesn't require refrigeration. This could potentially revolutionise vaccine distribution.
This groundbreaking initiative tests the tetanus-diphtheria vaccine (SPVX02) developed by Stablepharma, which stays perfectly stable at ambient temperatures. The company is optimistic about leveraging this technology to help up to 60 other vaccines avoid the fridge.
Currently, the vaccine's human trial is underway at the National Institute for Health and Care Research (NIHR) Southampton clinical research facility situated in University Hospital Southampton.
One of the major hurdles in immunization efforts, particularly in certain regions around the world, is maintaining the "cold chain" – the vital cool conditions from production until administration of the vaccine.
According to the World Health Organisation (WHO), nearly half of the vaccines globally are discarded each year, with improper temperature control and cold-chain logistical issues largely to blame
.Stablepharma, a UK-based biotech firm, has demonstrated that it can transform existing, approved vaccines into non-refrigerated versions with the potential for long-term room temperature storage.
Health and Social Care Secretary Wes Streeting applauded the development: "For years, vaccines have been held back by the need to be stored in a fridge – causing endless amounts of wastage and making it difficult to deliver them to remote communities."
He heralded what may be a turning point brought by this cutting-edge research: "But thanks to this Government's vision and our investment through the National Institute for Health and Care Research, all that could be about to change."
'We are leading the charge by pushing through the world's first trial for fridge-free vaccines.
"This could be a real game changer and lifesaver globally – as it unlocks new ways for poorer nations to deliver vaccines to their patients, where they're often needed the most."
The health secretary added: "Groundbreaking science is amongst the things that Britain does best, and this innovation reaffirms our position as a world leader in vaccine development and research, boosting growth and economic security – the cornerstone of our Plan for Change."
Professor Saul Faust from the University of Southampton and Dr Karen O'Hanlon, chief development officer at Stablepharma, are guiding the pivotal clinical trial.
Prof Faust said: "It is fantastic to see cutting-edge UK science reach the milestone of a first clinical trial and to be able to give the opportunity for people living on the south coast to take part.
"This research will be an important step toward exploring whether this innovation could eradicate vaccine wastage and move away from the need for the cold-chain."
Expectations are high that the study will wrap up by summer, with results awaiting release by year-end. With ambitious targets set by Stablepharma, the innovative vaccine could be deployed worldwide by 2027.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
2 minutes ago
- The Sun
Man, 45, died ‘taking de-worming drug for animals after seeing fake claims online it could cure cancer'
A MAN died after taking a de-worming drug for animals as he believed it would cure cancer, an inquest heard. Lee Redpath, 45, was rushed to hospital with signs of liver failure after dosing himself with an anti-parasitic drug called fenbendazole across a three-week period. 7 7 7 He tragically died in Addenbrooke's Hospital, in Cambridge, on April 29. Lee had ordered the drug, believing it to be safe, from a supplier in Ukraine. The 45-year-old saw fake social media posts which claimed fenbendazole could be a cancer cure - despite it being banned for human use. It's designed to be used against a number of gastrointestinal parasites in animals including giardia, roundworms, hookworms, whipworms, tapeworms and pinworms. However, even A-list celebrities have promoted the drug for humans, including actor Mel Gibson. He told Joe Rogan earlier this year how three of his friends were cured of stage four cancer after taking it with the anti-parasitic Ivermectin. The inquest, held in Lawrence Court, Huntingdon, Cambs, heard how Lee believed the de-wormer could prevent cancer. His long-term partner Lauren Laul gave evidence at the inquest. She told how her boyfriend believed it was safe to use and popular in the States. 'He saw it online, thought it was safe, people in America are using it," said Lauren. 'He didn't have medical assistance taking it so I think some sort of warning should be made. 'I am seeing it advertised online and people can get it themselves like Lee did and unknowingly be killing themselves because they didn't have all the information.' Lauren also suggested Lee may have been taking them for as long as two years before his death. Dr Gwilym Webb, a consultant hepatologist at Addenbrooke's warned fenbendazole had 'no proven benefit for preventing or treating cancer in humans.' 7 7 7 He told the inquest Lee was not eligible for a liver transplant due to alcohol misuse in the three months before. But a post-mortem concluded Lee's liver failure was due to the fenbendazole. Assistant coroner for Cambridgeshire and Peterborough, Caroline Jones, concluded Lee died of liver and renal failure due to fenbendazole induced liver injury on a background of alcohol related cirrhosis. 'I was satisfied as to the toxic effects of fenbendazole and that it was this that was the primary cause of the injury," she told the inquest. 'It is a potent anti-worming treatment which was taken at far higher relative doses than had ever been envisaged and over a far longer time scale. 'During his admission he advised doctors that he had been taking the drug fenbendazole, which he purchased online from a supplier in the Ukraine after seeing videos about its supposed anti-cancer properties. 'It was thought likely fenbendazole was the primary cause of the acute injury. Lee's conditions deteriorated despite treatment but he was not a candidate for transplant. 'He improved briefly but on April 27 his condition worsened, it was recognised Lee's organs were failing and he passed away at 6.06 pm on April 29. 'While Lee may have taken fenbendazole with good intentions to improve his health, it constituted a deliberate act with the unintended consequence of his death.' Lauren urged the coroner to write a prevention of future deaths report, but Miss Jones denied her request. The coroner said there was not "sufficient evidence", although she was "concerned" about people buying the drug online. Lee's death was recorded as misadventure. 7
The Independent
31 minutes ago
- The Independent
Patients whose lives were ruined after being ‘needlessly given cancer drug for years' sue NHS trust
More than 20 patients who say their quality of life was wrecked when they were needlessly given a highly toxic cancer drug are suing the NHS trust involved. Some people were prescribed temozolomide – which should normally be used for only six months – for more than a decade during treatment by the University Hospitals Coventry and Warwickshire NHS Trust. They say the overprescribing left them with side-effects including secondary cancers and crippling fatigue. Earlier this year the Care Quality Commission was looking into at least 14 cases, but lawyers say more are emerging all the time. An investigation by lawyers Brabners found that, over the past two decades, numerous patients with brain and spinal tumours under the care of Professor Ian Brown were routinely exposed to prolonged and in some cases 'unnecessary' use of the chemotherapy drug, which has severe side-effects including extreme fatigue, confusion, sickness and seizures. The time periods temozolomide was given for allegedly ran contrary to medical and scientific guidelines. Standard NHS procedure is to use the drug over six months, and the drug manufacturer advises it be used for up to 12 months. One man said he was prescribed it for nearly two years longer than necessary, suffering extreme fatigue and low mood as a result. A woman in her twenties said she was misdiagnosed with cancer, receiving the drug needlessly for about eight years. Some patients are now having treatment for secondary cancers allegedly linked to overuse of temozolomide, the lawyers claim. Others claimed its prolonged use left them unable to pursue career ambitions and normal day-to-day activities because the chemotherapy was debilitating, with a long recovery time. Some reported loss of fertility or abnormal blood test results. The legal team says data shows that the trust's spending on the drug of £3.6m from 2009 to 2024 is 10 times that of other NHS oncology departments. The lawyers are now calling for an extended patient safety review and independent investigation, focusing in particular on treatment received by patients under Prof Brown dating back to 2006. The trust has been conducting an internal patient safety review, covering 2017 to 2023, when Prof Brown retired. A patient who identified only as Michael received an extra 22 cycles of temozolomide at the trust, despite his scans being stable. Prof Brown was not present during consultations, and Michael said he was always seen by a clinical nurse specialist. After suffering extreme fatigue and low mood, he learnt through news reports of mistreatment –not from the trust – that he should not have remained on treatment for so long, according to his lawyers. Another patient, identified only as Becky, says she received at least 100 cycles of the drug unnecessarily after being misdiagnosed with a brain tumour. Fiona Tinsley, head of medical negligence at Brabners, said: 'The extent of this scandal, and the physical and mental impact it has had on Prof Brown's patients cannot be underestimated.' She added: 'We believe there are many more patients out there who haven't yet come forward and some who may have sadly passed away. 'While we welcome the ongoing investigations being undertaken by the General Medical Council and Royal College of Physicians, we believe a full independent inquiry is necessary – including an extension of the trust's own review back to 2006 – not only to ensure justice for victims, but that processes are put in place to better identify and prevent such failings happening again.' A spokesperson for the trust told The Independent: 'We have comprehensively reviewed and spoken to all individuals who were receiving temozolomide (TMZ) treatment at the end of 2023 to ensure appropriate support and care plans are in place. 'A glioblastoma is an aggressive brain tumour with fewer than two per cent of patients surviving longer than 10 years. This is an extremely complex condition and all modes of treatment – surgery, chemotherapy and radiotherapy – carry the risk of complications and side-effects. 'National Institute for Health and Care Excellence (Nice) guidelines recognise that clinicians can exercise professional judgment appropriate to individual circumstances when offering treatment to patients. 'We have commissioned the Royal College of Physicians to conduct an independent review of a representative cohort of patients who received greater than 12 cycles of adjuvant TMZ between 2017 and 2023. 'As this process is ongoing, it would be inappropriate to comment further at this stage." It's understood that CQC inspectors have been in touch with the trust to understand the details, and seek assurances that patients are not at risk. The regulator will be reviewing more information to judge whether it needs to be involved.
Daily Mail
an hour ago
- Daily Mail
The priming skin serum that banishes breakouts to leave skin glowing - and it uses a VERY unique ingredient: 'My skin has never looked so clear'
Daily Mail journalists select and curate the products that feature on our site. If you make a purchase via links on this page we will earn commission - learn more Clear skin can be difficult to achieve, especially if you have blemishes. You might find that you're either dealing with a breakout or the marks left behind. Both of those concerns are a job for the 47 Skin Anti-Blemish and Scar Repair Serum. This powerful serum takes no prisoners, working on contact to kill off 99.9 percent of the bacteria responsible for blemishes. There's nothing else like it, and it's all thanks to the unique compound known as Silver Chitoderm. 47 Skin Anti-Blemish and Scar Repair Serum Bacteria can run rampant on your skin, causing stubborn breakouts that are difficult to control. This serum works like a dream, killing 99.9 percent of them to leave skin clearer and brighter. In addition to reducing blemishes and marks, it also imparts moisture to give your skin a softer feel. You can even use it as a makeup primer! The results are astonishing, with many users sharing their impressive before and after results. Buy here Shop The brand harnessed the protective and healing properties of silver and coupled them with Chitoderm, which is formulated to create a protective and supportive barrier on the surface and essentially keep the silver right where it needs to be. Because the silver is concentrated right where you need it, it can target those unwanted marks with precision. Whether your concern is a blemish or a spot, you can rely on it to eradicate the bacteria and leave skin calmer and clearer. According to Dr. Sunil Chopra, a consultant dermatologist who founded the London Dermatology Centre, 'It decreases the production of melanin, which is often elevated in scars, reducing pigmentation over time.' And, unlike so many other treatments formulated to minimize those marks, 47 Skin's formula won't leave skin feeling tight and parched. In fact, it has the opposite effect thanks to ingredients like shea butter that soften skin to leave it feeling smoother and looking plumper. The beauty of the formula is that it works overtime, even doubling as a primer for makeup. That's key, because if you regularly wear makeup, you know how helpful primer can be — but very few offer the powerhouse skin care benefits that this serum delivers. The proof is in the consumer studies consisting of over 9,300 participants. Of those, a whopping 94 percent said they would buy the serum again, while 92 percent experienced a reduction in their spots. A whopping 90 percent said they had fewer scars, too. It's proven so effective that users have shared jaw-dropping before and after images revealing clarity and a brighter complexion. 'This is an excellent product. It has really smoothed out my complexion. The delivery was quick to boot. Very pleased,' raved one shopper. 'The acne has visibly decreased, as have my scars and uneven skin tone,' shared another. 'Overall it just looks so much better.' A third customer summed it up perfectly, stating: 'My skin has never looked so clear.' If you're chasing results like those, the 47 Skin Anti-Blemish and Scar Repair Serum could be just what your routine needs!
